Using claims data to identify the exact indication of use for biological drugs approved for immune-mediated inflammatory diseases: The VALORE project experience

被引：0
|
作者：
Spini, Andrea [1 ]
Ientile, Valentina [2 ]
Fontana, Andrea [3 ]
Ingrasciotta, Ylenia [4 ]
Tanaglia, Matilde [4 ]
Lopes, Sara [5 ]
Belleudi, Valeria [5 ]
Trifiro, Gianluca [4 ]
机构：
[1] Univ Verona, Verona, Italy
[2] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy
[3] Fdn IRCCS Casa Sollievo della Sofferenza, Unit Biostatist, San Giovanni Rotondo, Italy
[4] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy
[5] Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
596
引用
收藏
页码：277 / 278
页数：2
相关论文
共 26 条
  • [21] Comparative risk of venous thromboembolism (VTE) among patients with atopic dermatitis (AD) or other immune-mediated diseases: a cohort study using United States claims data
    Merola, Joseph F.
    Danwada, Raghava
    Ertmer, Brennan
    Liang, Huifang
    Ofori, Sarah
    Krueger, Whitney
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [22] Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database
    Tomio, Jun
    Yamana, Hayato
    Matsui, Hiroki
    Yamashita, Hiroyuki
    Yoshiyama, Takashi
    Yasunaga, Hideo
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (11) : 1674 - 1683
  • [23] Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
    Fautrel, Bruno
    Bouhnik, Yoram
    Salliot, Carine
    Carbonnel, Franck
    Fumery, Mathurin
    Bernardeau, Christophe
    Maugars, Yves
    Flamant, Mathurin
    Coury, Fabienne
    Braithwaite, Ben
    Hateb, Salima
    Addison, Janet
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (04) : 573 - 591
  • [24] Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study (vol 11, pg 573, 2024)
    Fautrel, Bruno
    Bouhnik, Yoram
    Salliot, Carine
    Carbonnel, Franck
    Fumery, Mathurin
    Bernardeau, Christophe
    Maugars, Yves
    Flamant, Mathurin
    Coury, Fabienne
    Braithwaite, Ben
    Hateb, Salima
    Addison, Janet
    PERFUSE Investigators
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 163 - 164
  • [25] The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91–108. doi:10.1007/s12325-016-0441-3
    Luis Cea-Calvo
    Loreto Carmona
    Jaime Calvo-Alén
    Advances in Therapy, 2017, 34 : 2173 - 2176
  • [26] The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91-108. doi:10.1007/s12325-016-0441-3
    Cea-Calvo, Luis
    Carmona, Loreto
    Calvo-Alen, Jaime
    ADVANCES IN THERAPY, 2017, 34 (09) : 2173 - 2176
123